FDA approves new use of popular diabetes drug
The FDA approved a new application for a popular diabetes drug to address weight loss. This decision occurs as the market for obesity treatments, specifically GLP-1 medications, faces intense commercial competition. While the FDA has granted this approval, current reports highlight a broader trend of peptides moving from clinical settings into unregulated wellness spas and smoke shops. This shift in accessibility happens alongside ongoing scrutiny regarding the safety and efficacy of various weight-loss solutions available to the public.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ The FDA approved a new application for a popular diabetes drug to address weight loss.
- ✓ This decision occurs as the market for obesity treatments, specifically GLP-1 medications, faces intense commercial competition.
- ✓ While the FDA has granted this approval, current reports highlight a broader trend of peptides moving from clinical settings into unregulated wellness spas and smoke shops.
What changed
The FDA approval for the diabetes drug's new use is now confirmed, though specific drug names remain absent from the latest reports.
Live updates
-
FDA Approves New Use for Diabetes Medication
The FDA approved a new application for a popular diabetes drug to address weight loss. This decision occurs as the market for obesity treatments, specifically GLP-1 medications, faces intense commercial competition. While the FDA has granted this approval, current reports highlight a broader trend of peptides moving from clinical settings into unregulated wellness spas and smoke shops. This shift in accessibility happens alongside ongoing scrutiny regarding the safety and efficacy of various weight-loss solutions available to the public.
Why it matters
Diabetes management is evolving globally as incidences rise in regions like India. The pharmaceutical market is currently seeing a surge in longevity and anti-aging treatments promoted by influencers and doctors.
Still unconfirmed
- Experimental peptides are being promoted by influencers, chiropractors, and longevity doctors for body optimization.
- Peptides are being sold in neighborhood smoke shops and wellness spas.
- Promotion of peptide supplements is misleading.
What to watch next
- Identification of the specific diabetes drug approved by the FDA.
- Regulatory actions regarding the sale of peptides in non-medical settings.
confidence 60%Sources used for this update (5)
- whyy.org — The rise of peptides: How the wellness craze is outpacing the science
- www.medpagetoday.com — Four Red Flags and One Truth Amid the Peptide Hype
- european-biotechnology.com — CHMP October decisions: AstraZeneca pulls prostate cancer filing; Orphelia gets a second chance; Ascendis nears EU launch
- www.forbesindia.com — Innovations are bringing in new ways to manage diabetes
- scitechdaily.com — Scientists Discover a Surprising New Effect of a Popular Blood Pressure Drug - SciTechDaily
-
FDA Approves New Use of Popular Diabetes Drug
The FDA has approved a new use for a popular diabetes drug, though the specific drug and new use are not detailed in the provided sources. This approval comes amid intense commercial interest in effective weight-loss solutions and ongoing concerns about the safety and efficacy of various weight-loss treatments. The approval may impact the competitive market for obesity treatments, which includes GLP-1 medications.
Why it matters
The pharmaceutical industry is closely watching the FDA's decisions on weight-loss treatments, especially given the popularity of GLP-1 medications like Ozempic, Wegovy, and Mounjaro. These medications have seen significant interest for their potential in treating obesity and related conditions, despite concerns about rare side effects. The market for weight-loss solutions is highly competitive, with various treatments in development and ongoing regulatory scrutiny.
What is confirmed
- GLP-1 drugs are being studied for benefits beyond diabetes and weight loss, including potential reductions in stroke and Alzheimer's risk.
- The GLP-1 market is highly competitive, with multiple treatments in development and significant commercial interest.
- There are ongoing concerns about the safety and efficacy of various weight-loss treatments, including rare side effects associated with GLP-1 medications.
Still unconfirmed
- A new weight loss drug, retatrutide, has shown up to 28.3% weight loss in trial results, but has not been approved by the FDA.
What to watch next
- Further details on the FDA-approved new use for the diabetes drug
- Ongoing regulatory scrutiny of weight-loss treatments
- Development and approval of other weight-loss drugs, including retatrutide
confidence 72%Sources used for this update (17)
- www.nbcnews.com — NBC News - Breaking Headlines and Video Reports on World, U.S....
- www.cnbc.com — Stock Markets, Business News, Financials, Earnings - CNBC
- abcnews.com — ABC News - Breaking News, Latest News and Videos
- fortune.com — What a desert lizard teaches us about patents and the GLP-1 revolution
- nchstats.com — What Is Reta? New Weight Loss Drug Retatrutide Shows Up to 28.3% Weight Loss, but FDA Has Not Approved It
- www.foxbusiness.com — Weight Loss - Fox Business ,Saving & Investing
- uwm.edu — Slow and Furious – Center for 21st Century Studies
- www.gayly.com — The Medical Minute: Is BMI telling the whole story? | The Gayly
- www.healthcareontime.com — Still Constipated After Milk of Magnesia? What to Do Next
- www.healthcareontime.com — Ataxia Telangiectasia: Symptoms, Outlook, and the New FDA Drug
- www.everydayhealth.com — Psoriasis Resource Center - Everyday Health
- help.naver.com — Futures Flat As Oil Rebounds After Trump's "Energy Ceasefire" Unravels, Memory Stocks Slide | ZeroHedge
-
Pfizer halts weight-loss drug candidate amid shifting market dynamics
Pfizer stopped development on an eagerly watched weight-loss drug candidate, altering the competitive market for obesity treatments. Meanwhile, the pharmaceutical industry continues to navigate intense commercial interest in effective weight-loss solutions. These treatments have previously seen physicians prescribing GLP-1 medications to children, alongside more than 200 lawsuits against manufacturers Eli Lilly and Novo Nordisk over rare eyesight conditions linked to drugs like Ozempic, Wegovy, and Mounjaro. Compounded telehealth products and affordable options from Canada also face mounting regulatory and enforcement hurdles.
Why it matters
The pharmaceutical industry faces high stakes in developing obesity treatments, drawing massive investor and researcher focus. At the same time, existing medications encounter legal scrutiny regarding severe side effects and growing restrictions on alternative acquisition methods.
What is confirmed
- Pfizer announced it was stopping a keenly observed weight-loss drug candidate.
- Physicians are prescribing GLP-1 medications to children for weight loss.
- Eli Lilly and Novo Nordisk face more than 200 lawsuits across the United States from plaintiffs alleging treatments trigger a rare condition threatening eyesight.
Still unconfirmed
- The weight-loss drug market will experience long-term instability following recent pipeline changes.
What to watch next
- Decisions by other major pharmaceutical companies regarding their weight-loss drug pipelines
- Developments in the federal lawsuits targeting Eli Lilly and Novo Nordisk over eyesight conditions
- Further regulatory enforcement actions against compounded GLP-1 telehealth products
confidence 80%Sources used for this update (3)
- www.thetechedvocate.org — Pfizer’s Weight Loss Drug Failure: Why This Game-Changing Market Just Got Wild
- www.hcplive.com — HCPLive Year in Review: Top 10 FDA Approvals for 2024 | HCPLive
- www.healthcareontime.com — Should You Quit Sweeteners on Antidepressants? What Science Says
-
Doctors Prescribe Children GLP-1s Amid Ongoing Regulatory Scrutiny
Physicians are prescribing GLP-1 medications to children for weight loss as the drugs gain widespread popularity. Meanwhile, pharmaceutical manufacturers Eli Lilly and Novo Nordisk face more than 200 lawsuits across the United States from plaintiffs alleging that treatments like Ozempic, Wegovy, and Mounjaro trigger a rare condition threatening their eyesight. Regulatory changes, including a 2025 presidential order ending the de minimis duty-free exemption for postal goods, could also affect American access to affordable pharmaceuticals from Canada. Compounded GLP-1 telehealth products continue to face strict enforcement and scrutiny from medical experts.
Why it matters
The expanding pediatric use of GLP-1 treatments intersects with a complex web of legal, regulatory, and supply challenges. Manufacturers like Eli Lilly continue developing new candidates such as retatrutide while managing extensive litigation over vision-threatening conditions. At the same time, shifting cross-border trade rules threaten traditional avenues for lower-cost medications, increasing reliance on domestic supply chains and compounding pharmacies.
What is confirmed
- Pharmaceutical manufacturers Eli Lilly and Novo Nordisk face more than 200 lawsuits across the United States over GLP-1 treatments.
- A 2025 presidential order ends the long-standing $800 de minimis duty-free exemption for goods coming into the U.S. via the postal system.
Still unconfirmed
- Giloy can act as a traditional fix for diabetes.
What to watch next
- Developments in federal enforcement against compounded GLP-1 telehealth products
- Legal rulings in the more than 200 lawsuits against Eli Lilly and Novo Nordisk
- Impact of the 2025 presidential order on American access to Canadian pharmaceuticals
confidence 90%Sources used for this update (7)
- www.everydayhealth.com — Health News: Latest Research, Top Stories, Trending Topics
- timesofindia.indiatimes.com — What is Giloy? Can this traditional secret fix diabetes
- politifact.com — Weight loss GLP-1s are everywhere and kids are taking them too. 7 things parents should know – PolitiFa....
- ca.news.yahoo.com — Rule changes could end Americans' access to cheap Canadian pharmaceuticals - Yahoo News Canada
- fortune.com — I'm an obesity expert and can't wait for the compounding craze to stop
- www.marketbeat.com — CX Institutional Sells 86,818 Shares of Medtronic PLC $MDT
- www.wral.com — Drugs News and Reporting Coverage, page 6 | WRAL
-
GLP-1 Drug Makers Face Lawsuits as Eli Lilly Advances Retatrutide
Pharmaceutical manufacturers Eli Lilly and Novo Nordisk face more than 200 lawsuits across the United States. Plaintiffs allege that popular GLP-1 weight-loss and diabetes treatments, including Ozempic, Wegovy, and Mounjaro, trigger a rare condition threatening their eyesight. Meanwhile, Eli Lilly continues its clinical development pipeline, reporting recent Phase 3 clinical trial results for its investigational triple-action weight management injection, retatrutide. These developments follow prior regulatory approvals that expanded diabetes medication indicators, such as clearances for Novo Nordisk's Ozempic to manage chronic kidney disease and Eli Lilly's daily dose of Jardiance for heart failure.
Why it matters
The mounting litigation introduces significant legal risk for top pharmaceutical companies as consumer adoption of GLP-1 medications surges for diabetes and weight control. At the same time, pipeline advancements like retatrutide demonstrate how drug makers continue pushing for more potent obesity treatments following earlier regulatory milestones for daily and weekly injections. These compounding factors place intense scrutiny on the safety profiles and market expansion strategies governing blockbuster metabolic therapies.
What is confirmed
- Novo Nordisk and Eli Lilly face a mountain of lawsuits numbering over 200 across the United States regarding popular GLP-1 medications.
- Eli Lilly developed an investigational drug called retatrutide that has completed Phase 3 clinical trials.
Still unconfirmed
- Popular weight-loss and diabetes drugs like Ozempic, Wegovy, and Mounjaro can trigger a rare, sight-threatening condition.
What to watch next
- Progression of the 200-plus lawsuits against Novo Nordisk and Eli Lilly in US courts
- Regulatory filing and FDA review timelines for Eli Lilly's retatrutide following Phase 3 clinical trials
confidence 80%Sources used for this update (4)
- www.thetechedvocate.org — Vision Loss Nightmare: Popular Weight Loss Drugs Spark 200+ Lawsuits
- www.thetechedvocate.org — This New Triple-Action Jab Could End Obesity for Good
- economictimes.indiatimes.com — British Indian pair, accused of cancer drug fraud, fight extradition to US
- www.marketbeat.com — Eli Lilly and Company (LLY) FDA Approvals, PDUFA Dates & Drug ...
-
FDA Approves New Indications for Diabetes Drugs Including Jardiance
The Food and Drug Administration has granted new approvals and indications for diabetes medications, expanding treatment options for patients managing chronic conditions. Eli Lilly and Boehringer Ingelheim secured approval for a daily dose of Jardiance to treat heart failure with reduced ejection fraction, creating market competition with AstraZeneca's Farxiga. Additionally, regulatory authorities cleared Novo Nordisk's Ozempic to prevent worsening kidney disease in type 2 diabetes patients. Meanwhile, Eli Lilly received approval for its once-weekly insulin injection, Onswik, and patients continue adopting its oral GLP-1 therapy, Foundayo.
Why it matters
Pharmaceutical companies are rapidly expanding the clinical applications of established diabetes therapies to address overlapping chronic health conditions such as heart and kidney disease. These regulatory decisions alter the commercial competition between major drug manufacturers while altering treatment regimens for patients. Concurrently, developers continue testing experimental compounds that may deliver further weight loss and health benefits if cleared by regulators.
What is confirmed
- Eli Lilly and Boehringer Ingelheim secured FDA approval for a 10mg daily dose of Jardiance to reduce cardiovascular death and heart failure hospitalization in adults with heart failure with reduced ejection fraction.
- Novo Nordisk's Ozempic became the first GLP-1 drug cleared by the FDA to prevent worsening kidney disease in type 2 diabetics.
- Eli Lilly received FDA approval for a once-weekly insulin injection named Onswik.
- One-third of all new patients starting an oral GLP-1 medication are choosing Eli Lilly's Foundayo.
Still unconfirmed
- Experimental drugs under development, such as EloraTZP, Trevogrumab, and CBL-154, may lead to significant weight loss if eventually approved by the FDA.
What to watch next
- Commercial market competition between Jardiance and Farxiga following the new regulatory clearance
- Potential FDA decisions regarding experimental weight loss and diabetes treatments currently under development
confidence 100%Sources used for this update (6)
- www.everydayhealth.com — What’s Next for Weight Loss Drugs? A Look at EloraTZP, Trevogrumab, and CBL-154 - Everyday Health
- finance.yahoo.com — Eli Lilly’s Foundayo delivers diabetes surprise in late-stage study
- www.fda.gov — What's New Related to Drugs | FDA - U.S. Food and Drug ...
- pharmaphorum.com — Ozempic is first GLP-1 drug FDA-approved for kidney disease
- pharmaphorum.com — Jardiance gets parity with Farxiga in US as FDA clears use in ...
- www.healthandme.com — From 365 Shots To 52: How Could Lilly’s Newly-Approved Weekly ...
-
Diabetes and Obesity Drug Trials Show Significant Weight Loss Results
Recent clinical findings indicate that experimental diabetes treatments and new pharmaceutical therapies achieve substantial reductions in body weight alongside blood sugar management. Research highlights therapies such as retatrutide and competitor compounds delivering major weight loss outcomes for patients managing obesity and type 2 diabetes. Meanwhile, regulatory tracking and patient safety discussions continue regarding side effects tied to widely used GLP-1 medications, spanning gastrointestinal issues to serious ocular risks.
Why it matters
These findings arrive amid shifting regulatory actions and intense public health scrutiny over diabetes and weight loss therapeutics. As drug developers race to improve efficacy metrics, patient advocacy and legal scrutiny focus heavily on the transparency of adverse health risks. Understanding the balance between clinical benefits and severe side effects remains central to ongoing pharmaceutical rollouts.
What is confirmed
- Experimental drug reta helps patients with type 2 diabetes and obesity manage blood sugar while losing an average of 20 percent of their body weight.
- Common Ozempic side effects include nausea and vomiting, while serious risks include NAION vision loss, gastroparesis, and pancreatitis.
Still unconfirmed
- A new obesity drug from Novo Nordisk called CagriSema leads to greater weight loss than the ingredient in Zepbound.
What to watch next
- Broader regulatory decisions on experimental diabetes and obesity treatments
- Further clinical data releases regarding combination GLP-1 therapies
- Developments in patient lawsuits concerning un-warned drug side effects
confidence 90%Sources used for this update (3)
- www.everydayhealth.com — Retatrutide Led to Significant Weight Loss in Newly Published Diabetes Trial - Everyday Health
- www.dailymail.com — New obesity drug leads to greater weight loss than ingredient in Zepbound
- www.drugwatch.com — Ozempic Side Effects: Common, Serious Risks & FDA Warnings
-
Eli Lilly Touts Foundayo Edge in Diabetes Analysis
Eli Lilly announced that its oral drug Foundayo delivered greater weight loss and A1C reduction than a higher dose of oral semaglutide at 52 weeks in a new indirect treatment comparison. This analysis emerges alongside broader regulatory actions in diabetes care, including the Food and Drug Administration approval of the once-weekly basal insulin injection Onswik. Meanwhile, public health discussions focus on off-label prescribing trends, potential interactions between cannabis and GLP-1 medications, and patient lawsuits concerning un-warned side effects like vision loss.
Why it matters
The diabetes medication market is expanding rapidly alongside rising off-label utilization across the United States. As pharmaceutical companies position new oral and injectable options for competitive advantage, patients and clinicians face growing questions regarding multi-substance interactions and long-term safety disclosures.
What is confirmed
- Eli Lilly stated that its oral obesity drug Foundayo offers greater weight loss and better blood sugar control than a higher dose of Novo Nordisk medication.
- Foundayo 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg at 52 weeks.
Still unconfirmed
- A physician and cannabinoid specialist warned of potential interactions between cannabis and GLP-1 drugs for a small percentage of users.
- Patients are suing makers of GLP-1 weight-loss drugs after experiencing vision loss without prior warnings.
- More than 1 million Americans are taking Ozempic and other GLP-1s without an approved reason.
What to watch next
- Additional clinical trial data or regulatory updates regarding Foundayo and oral semaglutide
- Developments in patient lawsuits against GLP-1 drug manufacturers regarding vision loss warnings
confidence 90%Sources used for this update (8)
- www.fox32chicago.com — Doctor warns of potential interactions between GLP-1 drugs and cannabis
- www.marketscreener.com — Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment ...
- finance.yahoo.com — Lilly touts Foundayo advantage over Novo's Ozempic pill in diabetes analysis
- www.today.com — Woman Details Losing Vision After Taking Wegovy As Patients Sue GLP-1 Drug Companies - TODAY
- gizmodo.com — More Than 1 Million Americans Are Taking Ozempic and Other GLP-1s Without an Approved Reason. Is That Act....
- www.ama-assn.org — 5 things patients should know about GLP-1 medications
- www.fda.gov — FDA Approves Once-Weekly Insulin for Type 2 Diabetes Mellitus
- economictimes.indiatimes.com — Cashless health insurance claims: What policyholders can do when hospitals and insurers clash over bills,....
-
FDA Approves Onswik Once-Weekly Insulin
The Food and Drug Administration approved Onswik, a once-weekly basal insulin injection designed to help adults with type 2 diabetes manage their blood glucose levels. Developed by Eli Lilly, the medication is intended to be used alongside diet and exercise to maintain glycemic control by providing steady levels of basal insulin over a seven-day period. This approval follows earlier regulatory actions addressing diabetes complications, such as the approval of Kerendia for chronic kidney disease in type 1 diabetes patients.
Why it matters
Daily basal insulin injections have long formed a cornerstone of diabetes management, but adherence remains a major hurdle for patients. A once-weekly dosing schedule aims to reduce injection frequency and potentially improve long-term glycemic outcomes. Regulatory bodies continue to clear therapies that simplify chronic disease management routines.
What is confirmed
- The Food and Drug Administration approved Onswik as a once-weekly basal insulin for adults with type 2 diabetes.
- Eli Lilly developed the once-weekly therapy to control glucose levels alongside diet and exercise.
- The drug delivers steady levels of basal insulin over a seven-day period.
What to watch next
- Commercial availability and market launch date for Onswik
- Pricing and insurance coverage announcements from Eli Lilly
confidence 100%Sources used for this update (4)
- www.thewrap.com — The Top 21 New Movies Streaming Now
- finance.yahoo.com — U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell ...
- beyondtype1.org — FDA Approves Onswik: A Once-Weekly Insulin For Adults With Type 2 Diabetes
- www.deseret.com — Written in blood: Disease discovery keeps expanding with new tests
-
FDA approves Onswik once-weekly basal insulin for type 2 diabetes
The FDA approved Onswik, a once-weekly basal insulin injection developed by Eli Lilly, to control glucose levels in adults with type 2 diabetes. Patients use the therapy alongside diet and exercise to maintain glycemic control. The drug provides steady levels of basal insulin over a seven-day period. This approval follows previous regulatory action regarding diabetes complications, such as the approval of Kerendia for chronic kidney disease in type 1 diabetes patients.
Why it matters
Basal insulin provides a steady level of insulin to regulate blood sugar between meals and overnight. Reducing injection frequency from daily to weekly doses may improve patient adherence. This occurs as the FDA faces leadership transitions with the nomination of Dr. Heidi Overton.
What is confirmed
- The FDA approved Onswik, a once-weekly basal insulin injection, for adults with type 2 diabetes.
- Onswik is indicated for use alongside diet and exercise to control high blood sugar.
- Eli Lilly developed the therapy to deliver steady basal insulin levels for 7 days.
What to watch next
- Senate hearing testimony from FDA nominee Dr. Heidi Overton regarding agency policy
confidence 100%Sources used for this update (3)
- www.healio.com — FDA approves Onswik, a once-weekly basal insulin, for adults with type 2 diabetes
- krdo.com — Trump’s nominee to lead FDA faces questions on vaccines, abortion in Senate hearing
- www.marketscreener.com — Eli Lilly and Company Receives U.S. Food and Drug Administration Approval of Onswik as Once-Weekly Basal Insulin Injection Treatment for Adults Living with Type 2 Diabetes
-
FDA approves Kerendia for type 1 diabetes linked kidney disease
The FDA approved Bayer's Kerendia (finerenone) for adults with chronic kidney disease caused by type 1 diabetes. This once-daily oral nonsteroidal mineralocorticoid receptor antagonist aims to lower the risk of end-stage kidney disease and sustained estimated glomerular filtration rate decline. Bayer states this is the first new treatment for this specific patient group in 30 years. The decision followed a Priority Review of a supplemental New Drug Application and data from the phase 3 FINE-ONE trial. The drug works by reducing the urinary albumin-to-creatinine ratio.
Why it matters
Chronic kidney disease is a common complication of type 1 diabetes that often requires specialized pharmaceutical intervention to prevent total organ failure. This approval expands the utility of Kerendia beyond its previous indications.
What is confirmed
- The FDA approved Kerendia for adults with chronic kidney disease linked to type 1 diabetes.
- Kerendia is a once-daily oral nonsteroidal mineralocorticoid receptor antagonist.
- The approval was based on results from the phase 3 FINE-ONE trial.
What to watch next
- Clinical data on long-term patient outcomes following the FINE-ONE trial
confidence 100%Sources used for this update (3)
- abc7ny.com — What GLP-1 users should know about the potential risk of a rare type of vision loss
- www.marketscreener.com — Weight-loss drug developers line up to tap lucrative market as competition heats up
- www.marketscreener.com — Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020
-
FDA approves Kerendia for type 1 diabetes kidney disease
The FDA has approved Bayer's Kerendia (finerenone) for adults with chronic kidney disease linked to type 1 diabetes. This once-daily oral nonsteroidal mineralocorticoid receptor antagonist reduces the urinary albumin-to-creatinine ratio. According to Bayer, this represents the first new treatment for this patient population in 30 years. The approval followed a Priority Review of a supplemental New Drug Application based on results from the phase 3 FINE-ONE trial. The medication is intended to lower the risk of sustained estimated glomerular filtration rate decline and end-stage kidney disease.
Why it matters
Chronic kidney disease is a severe complication of diabetes that can lead to total organ failure. By targeting the mineralocorticoid receptor, this drug offers a new therapeutic path for patients who previously lacked recent medical advancements.
What is confirmed
- The FDA approved Kerendia for adults with chronic kidney disease associated with type 1 diabetes.
- Kerendia is a once-daily oral nonsteroidal mineralocorticoid receptor antagonist.
- The drug lowers the urinary albumin-to-creatinine ratio.
- FDA approval relied on data from the phase 3 FINE-ONE trial.
Still unconfirmed
- This is the first new treatment for this specific patient group in 30 years.
What to watch next
- Clinical data on long-term patient outcomes following the FINE-ONE trial implementation.
- Insurance coverage and accessibility updates for Kerendia in type 1 diabetes patients.
confidence 100%Sources used for this update (2)
- finance.yahoo.com — Largest Kidney Patient Group Applauds HHS Secretary Robert F. Kennedy Jr.'s Appointments to the U.S. Preventive Services Task Force
- ana.ir — Reddit sheds light on drug side effects
-
FDA approves Kerendia for chronic kidney disease in type 1 diabetes patients
The FDA approved Bayer's Kerendia (finerenone) for adults with chronic kidney disease associated with type 1 diabetes. This once-daily oral nonsteroidal mineralocorticoid receptor antagonist lowers the urinary albumin-to-creatinine ratio. Bayer states this approval is the first new treatment for this specific patient group in 30 years. The decision follows a Priority Review of a supplemental New Drug Application and relies on data from the phase 3 FINE-ONE trial. The drug aims to reduce the risk of end-stage kidney disease and sustained estimated glomerular filtration rate decline.
Why it matters
Chronic kidney disease is a common complication of type 1 diabetes that can lead to total kidney failure. This approval adds a targeted pharmacological option to a treatment landscape that recently saw the introduction of the Beta Bionics Mint insulin pump and expanded uses for Mounjaro.
What is confirmed
- The FDA approved finerenone (Kerendia) to lower urinary albumin-to-creatinine ratio in adults with chronic kidney disease associated with type 1 diabetes.
- Kerendia is a once-daily oral nonsteroidal mineralocorticoid receptor antagonist.
- The approval was based on data from the phase 3 FINE-ONE trial.
- Bayer announced the approval on September 17, 2026.
Still unconfirmed
- Kerendia is the first new treatment in 30 years for adults with chronic kidney disease and type 1 diabetes.
- Novo signed a drug discovery and licensing agreement with Orbis Medicines valued at up to $1.4 billion for oral cardiometabolic drugs.
What to watch next
- Clinical outcomes regarding the reduction of end-stage kidney disease in the general T1D population.
- Further FDA approvals for oral cardiometabolic therapies resulting from the Novo and Orbis partnership.
confidence 100%Sources used for this update (4)
- finance.biggo.com — Novo Strikes Up-to-$1.4 Billion Deal With Orbis to Chase Oral Cardiometabolic Drugs
- www.healio.com — FDA approves Kerendia for adults with CKD associated with type 1 diabetes
- finance.yahoo.com — Bayer’s KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes
- finance.yahoo.com — Fetal Monitoring Devices Market Set for Growth Through 2034, Fueled by Rising Maternal Care Demand, Noninvasive Technologies, and Wireless Monitoring Innovation
-
FDA clears Beta Bionics reusable insulin patch pump
The FDA cleared Mint, a reusable insulin patch pump from Beta Bionics for people with diabetes. The device features a 200U insulin reservoir and operates for up to 3 days, with an added 12-hour grace period. Unlike some competitors, this pump functions for multiple days without requiring a recharge. This regulatory approval expands delivery options for patients alongside recent developments in diabetes pharmacotherapy, including the expanded use of Eli Lilly's Mounjaro for cardiovascular risk reduction in adults with type 2 diabetes.
Why it matters
Insulin delivery technology focuses on reducing patient burden through smaller form factors and longer wear times. These hardware updates coincide with a shift toward GLP-1 medications for both glucose control and weight loss. Recent data also suggests these medications may cause nutritional deficiencies leading to rare brain disorders.
What is confirmed
- The FDA cleared the Mint insulin patch pump for people with diabetes.
- The Mint pump contains a 200U insulin reservoir.
- The device can be used for up to 3 days with a 12-hour grace period.
- The pump operates for multiple days without recharging.
What to watch next
- Clinical data on the long-term impact of GLP-1 appetite suppression on B1 vitamin levels
- Further results from Corbus Pharmaceuticals regarding the CRB-913 weight loss drug
confidence 100%Sources used for this update (3)
- www.healio.com — FDA clears reusable insulin patch pump for people with diabetes
- markets.ft.com — Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain
- muddyriversports.com — AlkaTide Reviews 2026 (URGENT REPORT) Consumer Research Examines Ingredients, Benefits, Pricing, and Refund Terms
-
GLP-1s Linked to Rare Brain Disorder as New Obesity Drug Shows Promise
Researchers have identified a link between GLP-1 medications and Wernicke encephalopathy, a rare brain disorder caused by vitamin B1 deficiency. Experts suggest the medications' appetite suppression may lead to nutritional gaps despite constant bodily requirements. Separately, Corbus Pharmaceuticals reported positive topline data from its CANYON-1 study, where the daily oral drug CRB-913 achieved a statistically significant mean weight loss of 5% at 60 mg after 12 weeks without a plateau. These updates follow the FDA's approval of Eli Lilly's Mounjaro for cardiovascular risk reduction in adults with type 2 diabetes.
Why it matters
GLP-1 therapies are expanding from glucose control to obesity treatment and cardiovascular prevention. The emergence of nutritional deficiencies highlights potential safety trade-offs as these drugs reach broader populations, including children and teens.
What is confirmed
- CRB-913 showed statistically significant mean weight loss of 5% at 60 mg after 12 weeks in the CANYON-1 study.
- The FDA approved Mounjaro to lower heart attack or stroke risk in adults with type 2 diabetes.
Still unconfirmed
- Appetite suppression from GLP-1s makes it easier for some users to suffer vitamin deficiencies.
What to watch next
- Clinical trials for CRB-913 beyond the 12-week mark
- FDA review of GLP-1 safety profiles regarding vitamin B1 deficiency
confidence 90%Sources used for this update (4)
- www.medpagetoday.com — Nurse Accused of Exorcism; Death After 8 Hours of Plastic Surgery; Top Cancer Months
- markets.businessinsider.com — Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity
- finance.biggo.com — Andrew Huberman: The MDMA Therapy Setback Wasn't the Drug — It Was the Wild West Around It
- kffhealthnews.org — GLP-1s May Be Linked To Rare Brain Disorder Caused By B1 Deficiency
-
FDA expands Mounjaro use for heart and stroke risk reduction
The FDA approved Eli Lilly and Company's Mounjaro to lower the risk of stroke or heart attack in adults with type 2 diabetes. This move shifts the drug's application from simple glucose control to cardiovascular prevention. While GLP-1 therapies are gaining traction, children and teens with diabetes and obesity are also increasingly using these treatments. Other pharmaceutical developments include Kura Oncology's $50 million launch of Caspian Therapeutics to study menin inhibition for diabetes, contrasting with the high cost of Revolution Medicines' cancer drug Rasonque.
Why it matters
GLP-1 medications are evolving from diabetes treatments into broader metabolic and cardiovascular tools. High costs for specialized therapies like Rasonque create insurance barriers for patients. Current medical debate focuses on the long-term safety of using these drugs in pediatric populations.
What is confirmed
- The FDA approved Mounjaro to reduce the risk of stroke or heart attack in adults with type 2 diabetes.
- Kura Oncology launched Caspian Therapeutics with $50 million in financing to research menin inhibition for diabetes.
- Revolution Medicines' Rasonque costs approximately $480,000 per year or $663 per tablet.
Still unconfirmed
- Children and teens with obesity and diabetes are increasingly using GLP-1 therapy.
What to watch next
- Clinical data on the long-term effects of GLP-1 drugs in pediatric patients.
- Insurance coverage updates for Rasonque.
confidence 90%Sources used for this update (4)
- finance.yahoo.com — Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth
- finance.biggo.com — FDA's Vanishing Advisory Panels: Mike McCaughan Sees a 'Real Loss' as Drug Reviews Go Quiet
- www.biopharmadive.com — Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
- gizmodo.com — What Do We Actually Know About Kids on Weight-Loss Drugs?
-
FDA expands Mounjaro use for heart and stroke risk in diabetes patients
The FDA approved Eli Lilly and Company's Mounjaro to reduce the risk of heart attack or stroke in adults with type 2 diabetes. While this expands the drug's use beyond glucose control, other new therapies face accessibility issues. Revolution Medicines' pancreatic cancer drug Rasonque carries a sticker price of approximately $480,000 per year, or $663 per tablet, contributing to insurance coverage delays. Meanwhile, Kura Oncology has launched Caspian Therapeutics with $50 million in financing to research menin inhibition as a potential disease-modifying treatment for diabetes.
Why it matters
The approval of Mounjaro reflects a shift toward using diabetes medications for broader cardiovascular protection. This occurs amid rising costs for oncology drugs and a growing patient trend of seeking treatments outside regulated health systems. New investments in menin inhibition suggest a search for alternatives to existing diabetes therapies.
What is confirmed
- The FDA approved Eli Lilly and Company's Mounjaro to lower the risk of stroke or heart attack in adults with type 2 diabetes.
- Revolution Medicines set a sticker price of about $480,000 a year, or $663 a tablet, for Rasonque.
- Kura Oncology launched Caspian Therapeutics with $50 million in financing to advance menin inhibition for diabetes.
- The FDA approved a daily pill for adults with advanced breast cancer whose tumors resisted previous treatments.
Still unconfirmed
- Patients are looking beyond the regulated health system to address problems doctors struggle to treat as part of a peptide craze.
What to watch next
- Insurance company decisions on Rasonque coverage
- Clinical trial results for Caspian Therapeutics' menin inhibition approach
confidence 90%Sources used for this update (4)
- www.smithsonianmag.com — Peptides Are All the Rage, Promising Miracle Cures and Makeovers Delivered by Injection. How Did We Get Here?
- www.medicalbrief.co.za — Staggering cost of pancreatic cancer pill the ‘new normal’
- markets.businessinsider.com — Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes
- www.wcax.com — Aging Untold experts share personal weight-loss journeys
-
FDA expands Mounjaro use for heart and stroke risk reduction
The FDA approved Eli Lilly and Company's Mounjaro to lower the risk of stroke or heart attack in adults with type 2 diabetes. This approval extends the drug's clinical application beyond glucose management. While Mounjaro gains this new indication, other recently approved therapies face different hurdles. Patients seeking the pancreatic cancer drug Rasonque from Revolution Medicines continue to encounter insurance coverage delays due to an administrative gap. Additionally, the FDA approved a daily pill for adults with advanced breast cancer whose tumors resisted previous treatments.
Why it matters
Mounjaro is a GLP-1 receptor agonist. Expanding its use to cardiovascular protection increases its utility in the diabetes treatment market. The contrast with Rasonque highlights a recurring disconnect between regulatory approval and actual patient access.
What is confirmed
- The FDA approved Mounjaro to reduce heart attack or stroke risk in adults with type 2 diabetes.
- The FDA approved a daily pill for adults with advanced breast cancer whose tumors bypassed current treatments.
- An administrative gap is delaying insurance coverage for Revolution Medicines' pancreatic cancer drug, Rasonque.
What to watch next
- Resolution of the administrative gap affecting Rasonque coverage
- Clinical data on the efficacy of the new advanced breast cancer pill
confidence 100%Sources used for this update (4)
- www.statnews.com — An administrative gap delays access to new pancreatic cancer treatment
- muddyriversports.com — Tinnoril Reviews and Complaints 2026 – Real Tinnitus Support or Overhyped Hearing Supplement?
- medicalxpress.com — FDA approves new pill for advanced breast cancer guided by blood test
- markets.businessinsider.com — Replacing Insulin Cells Works. Keeping The Cells Alive Is the Trick
-
FDA Approves Mounjaro to Reduce Heart Attack and Stroke Risk
The U.S. Food and Drug Administration has approved Eli Lilly and Company's Mounjaro to reduce the risk of heart attack or stroke in adults with type 2 diabetes. This regulatory expansion reinforces the drug's position as a major growth driver within the diabetes treatment sector. Meanwhile, patients continue to experience insurance coverage delays following FDA approvals for other therapies such as Revolution Medicines' pancreatic cancer drug, Rasonque. Separately, a clinical study published by Insilico Medicine demonstrates that an artificial intelligence-designed drug candidate reverses biological age.
Why it matters
Regulatory approvals shape pharmaceutical market growth and dictate how quickly patients can access critical therapies. While new indications for established drugs like Mounjaro expand treatment utility for diabetes patients, separate coverage hurdles persist across newly approved medications. Market forecasts project substantial expansion driven by emerging oral therapies.
What is confirmed
- The FDA approved Mounjaro to reduce the risk of heart attack or stroke in adults with type 2 diabetes.
- Insilico Medicine published a study showing an artificial intelligence-designed drug candidate reverses biological age.
- Patients face insurance coverage delays after the FDA approves new drugs like Revolution Medicines' pancreatic cancer treatment, Rasonque.
Still unconfirmed
- The obesity market is forecast to expand at approximately 27% compound annual growth rate through 2036.
What to watch next
- Insurance coverage decisions for newly approved therapies
- Market growth and adoption rates of oral GLP-1 therapies through 2036
confidence 100%Sources used for this update (4)
- www.news-medical.net — AI-designed drug candidate reverses biological age in clinical study
- finance.yahoo.com — Could Mounjaro’s New Heart Benefit Unlock the Next Growth Phase for Lilly?
- uk.finance.yahoo.com — Obesity Market Insights, Epidemiology & Forecast 2026-2036 | Obesity Market Forecast to Expand at Approximately 27% CAGR Through 2036 as Oral GLP-1 Therapies and Pipeline ...
- www.statnews.com — A breakthrough pancreatic cancer drug won approval. They still struggle to access it
-
FDA Approves New Diabetes and Polycythemia Vera Treatments
The U.S. Food and Drug Administration has approved Takeda Pharmaceuticals' Mimrylo as a new treatment for adults with polycythemia vera who lack adequate control with existing therapies. Meanwhile, regulatory and health updates continue across the pharmaceutical sector, including recent approvals for updated seasonal vaccines and breast cancer treatments. While medications such as Ozempic, Wegovy, and Zepbound show major health improvements, researchers are examining patient concerns including hair thinning. Medical providers also emphasize modern metrics like fat distribution over traditional body mass index standards for chronic weight management.
Why it matters
Regulatory decisions by federal health agencies directly dictate clinical availability and treatment pathways for millions of patients managing chronic illnesses. The expanded approvals arrive alongside ongoing shifts in how physicians evaluate metabolic health and obesity. Monitoring these therapeutic milestones helps patients and clinicians navigate evolving treatment guidelines.
What is confirmed
- The U.S. Food and Drug Administration approved Takeda Pharmaceuticals' Mimrylo as a new treatment for adults with polycythemia vera who have not achieved adequate control with existing therapies.
Still unconfirmed
- Hair thinning has become an increasingly discussed concern among people using drugs such as Ozempic, Wegovy, and Zepbound.
What to watch next
- Further clinical data regarding hair loss side effects in GLP-1 medications
- Patient adoption rates for newly approved treatments
confidence 100%Sources used for this update (17)
- medicalxpress.com — FDA approves first-in-class drug for polycythemia vera
- knowridge.com — Why Some Men on Weight Loss Drugs Get Hair Loss
- www.pharmabiz.com — AES Cleanroom Technology’s modular wall and ceiling panels receive FM 4882 approval to address cleanroom risk
- www.pharmabiz.com — FibroBiologics receives US patent for the therapeutic use of fibroblasts in wound healing
- medicaldialogues.in — FDA Grants Accelerated Approval to a New Breast Cancer Treatment
- www.news-medical.net — New prostate cancer screening advances improve early detection
- www.explorejeffersonpa.com — The Medical Minute: Does BMI Tell the Whole Weight Loss Story?
- www.medpagetoday.com — 'She Was Cussing Us Up One Side and Down the Other': What We Heard This Week
- www.latimes.com — A Doctor Who Uses Peptides Explains Why He’s Cautious About BPC-157
- timesofindia.indiatimes.com — Judge orders Trump admin to give 48-hour notice before work on 250ft Arlington arch
- www.hindustantimes.com — FDA awaiting response from restaurants at Mumbai Cricket Association premises: Mundhe
- www.timesleader.com — Top US doctors offer updated flu and COVID vaccine recommendations, aiming to ease confusion
-
FDA expands Mounjaro use as Eli Lilly battles black market for next obesity drug
The FDA approved Eli Lilly's Mounjaro to reduce major adverse cardiovascular event risks for high-risk adults with type 2 diabetes. While this expands the drug's clinical utility, Eli Lilly is now fighting a booming black market for retatrutide, an experimental injectable that outperformed previous obesity medications in clinical trials. This development occurs as GLP-1 use increases among U.S. children under 12 despite a lack of FDA approval. Access remains limited for some patients due to high costs and specific medical disqualifications within the Medicare Bridge pilot program.
Why it matters
GLP-1 drugs are becoming central to treating obesity and heart disease. Eli Lilly is leveraging these approvals to maintain coverage with insurers as some policies decline toward 2027. The emergence of next-generation drugs like retatrutide highlights the high demand and resulting illicit trade.
What is confirmed
- The FDA approved Mounjaro to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes who face high risk.
- The Medicare Bridge pilot program excludes certain eligible individuals based on specific medical disqualifications.
Still unconfirmed
- A booming black market exists for the experimental drug retatrutide.
What to watch next
- FDA approval status for GLP-1 use in children under 12
- Clinical trial results and official FDA filing for retatrutide
- Changes to employer and insurer coverage for GLP-1 drugs leading into 2027
confidence 80%Sources used for this update (5)
- www.ibtimes.com.au — New Study Links Xylitol Sweetener To Higher Heart Attack And Stroke Risk In 17,700 People, Cardiologist Warns
- www.aol.com — GLP-1 use in US kids under-12 soars - even without FDA approval
- www.nola.com — Waiting for retatrutide: A ‘blockbuster’ new drug could help reduce Louisiana obesity rates
- www.ibj.com — Lilly fighting black market for its next obesity drug
- www.miamitimesonline.com — Top US doctors offer updated flu and COVID vaccine recommendations, aiming to ease confusion
-
FDA expands Mounjaro use for cardiovascular risk in type 2 diabetes
The FDA approved Eli Lilly's Mounjaro (tirzepatide) to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes who face high risk for such events. This approval strengthens Eli Lilly's position in negotiations with employers and insurers as GLP-1 drug coverage declines toward 2027. While the drug's utility expands, patient access remains a hurdle; some patients cannot afford the monthly costs of related drugs like Zepbound, and the Medicare Bridge pilot program excludes certain eligible individuals based on specific medical disqualifications.
Why it matters
GLP-1 medications are increasingly used for both diabetes and weight loss. This specific approval shifts Mounjaro's clinical application toward preventative heart health. The timing is critical as healthcare payers tighten restrictions on these expensive therapies.
What is confirmed
- The FDA approved Mounjaro to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for these events.
- The Medicare Bridge pilot program excludes some individuals who would benefit from drugs such as Zepbound, Wegovy, and Ozempic.
Still unconfirmed
- Jeff La Marca was unable to afford a 750 dollar monthly price tag for Zepbound in January.
What to watch next
- Updates on Medicare Bridge pilot program eligibility criteria
- Changes in insurance coverage rates for GLP-1 drugs heading into 2027
confidence 90%Sources used for this update (8)
- tucson.com — Updated flu shots are available in Arizona. Should you get one now?
- www.texarkanagazette.com — The Medicare GLP-1 discount has one big catch: Some sick patients don't qualify
- www.rttnews.com — 6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More
- finance.yahoo.com — Medicare's $50 GLP-1 Bridge plan won't cover a morbidly obese NJ man because his sleep apnea disqualifies him
- www.prevention.com — COVID Cases Are Climbing Across the Country—Here Are the Top Symptoms to Expect in 2026
- muddyriversports.com — BloodPril Reviews 2026 – Legit Blood Pressure Support or Overhyped Supplement?
- www.statnews.com — Ionis wins FDA approval for first drug for Alexander disease, a rare and deadly neurological disorder
- www.el-balad.com — Leading U.S. groups issue Covid, Flu And Rsv Vaccine Recommendations
-
FDA Approves Mounjaro for Cardiovascular Risk Reduction in Type 2 Diabetes
The FDA has approved Eli Lilly's Mounjaro (tirzepatide) for a new use to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes. This expansion targets patients who are at high risk for cardiovascular events. The approval provides Eli Lilly with a strategic advantage in negotiations with insurers and employers at a time when coverage for GLP-1 drugs is declining heading into 2027.
Why it matters
Mounjaro belongs to a class of GLP-1 drugs used for diabetes and weight management. This new indication allows the drug to be marketed specifically for heart health rather than just glucose control. It positions Lilly against competitors like Novo Nordisk in the cardiovascular market.
What is confirmed
- The FDA approved Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes.
- Mounjaro is approved to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for CV events.
Still unconfirmed
- Employer coverage of GLP-1 drugs is collapsing heading into 2027.
- An Amgen drug could target a cardiovascular market that rivals the value of Eli Lilly's GLP-1 drugs.
What to watch next
- Changes in insurance coverage policies for GLP-1 drugs following the cardiovascular approval
- Clinical data or approval updates for Amgen's cardiovascular drug pipeline
confidence 100%Sources used for this update (11)
- Eli Lilly and Company — FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
- Fierce Pharma — Lilly scores Novo-pressuring Mounjaro expansion to curb heart risks in diabetes patients
- USA Today — Eli Lilly's diabetes drug Mounjaro gets approval for a new use
- Time Magazine — Mounjaro Is Now Approved to Lower the Risk of Heart Events
- Action News 5 — FDA approves new use of popular diabetes drug
- www.thecardiologyadvisor.com — Mounjaro Approved to Reduce MACE Risk in Adults With T2DM
- finance.yahoo.com — Insurers Are Pulling Back From GLP-1 Drugs. The FDA Just Handed Eli Lilly Its Best Weapon Yet
- finance.yahoo.com — Fractyl Health Eyes 2028 Revita Launch for Post-GLP-1 Weight Maintenance
- 247wallst.com — Jim Cramer: This Little-Talked-About Drug Could Target the “Biggest Market of All Time” Aside From Eli Lilly’s GLP-1 Drugs
- www.aol.com — Yes, You Can Reverse Fatty Liver Disease—and Boost Weight Loss After 50
- uk.finance.yahoo.com — Mesenchymal Stem Cells / Medicinal Signaling Cells (MSCs) Report Now Available — Delivers Pipeline Visibility and Deal-Grade Competitive Intelligence on 125 Companies Shaping ...
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community